Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MANNKIND CORPMNKD · Entity 4792 | EVP Technical Operations | July 15, 2026 | July 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MANNKIND CORP
Report date July 15, 2026 · Filed July 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 478,966 |
Ending reported balance
After 2026-07-15 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-07-15 · Exercise / conversion · Acquired 70,550 · Balance 525,761 F1: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 70,550 shares. The acquisition of 85,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 14,450 shares were forfeited in accordance with the performance vesting criteria. Row 2 · 2026-07-15 · Tax withholding · Disposed 22,047 · Balance 503,714 F2: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Row 3 · 2026-07-15 · Tax withholding · Disposed 5,372 · Balance 498,342 F2: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Row 4 · 2026-07-15 · Tax withholding · Disposed 10,079 · Balance 488,263 F2: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Row 5 · 2026-07-15 · Tax withholding · Disposed 9,297 · Balance 478,966 F2: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Performance Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-15 · Exercise / conversion · Disposed 70,550 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F1: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 70,550 shares. The acquisition of 85,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 14,450 shares were forfeited in accordance with the performance vesting criteria. |
Filing footnotes · ownership attribution and instrument terms
F1: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 70,550 shares. The acquisition of 85,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 14,450 shares were forfeited in accordance with the performance vesting criteria.
F2: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.
F3: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 18, 2026 01:44 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionPerformance Restricted Stock Unit · Derivative | 70,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-308132 · ownership.xml · derivative · entry 6 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.01 Par Value · 70,550 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F1 · kind: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 70,550 shares. The acquisition of 85,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 14,450 shares were forfeited in accordance with the performance vesting criteria. F1 · derivative.exercise_date: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 70,550 shares. The acquisition of 85,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 14,450 shares were forfeited in accordance with the performance vesting criteria. F1 · derivative.expiration_date: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 70,550 shares. The acquisition of 85,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 14,450 shares were forfeited in accordance with the performance vesting criteria. F1 · balance_after: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 70,550 shares. The acquisition of 85,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 14,450 shares were forfeited in accordance with the performance vesting criteria. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:44 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 9,297 | $4.09 | $38,024.73 |
DisclosureSEC source: 0001193125-26-308132 · ownership.xml · nonDerivative · entry 5 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 478,966 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:44 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 10,079 | $4.09 | $41,223.11 |
DisclosureSEC source: 0001193125-26-308132 · ownership.xml · nonDerivative · entry 4 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 488,263 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:44 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 5,372 | $4.09 | $21,971.48 |
DisclosureSEC source: 0001193125-26-308132 · ownership.xml · nonDerivative · entry 3 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 498,342 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:44 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 22,047 | $4.09 | $90,172.23 |
DisclosureSEC source: 0001193125-26-308132 · ownership.xml · nonDerivative · entry 2 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 503,714 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:44 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionCommon Stock, $0.01 Par Value | 70,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-308132 · ownership.xml · nonDerivative · entry 1 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 525,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 70,550 shares. The acquisition of 85,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 14,450 shares were forfeited in accordance with the performance vesting criteria. Read SEC document |
| March 23, 2026 Filed Mar 26, 2026 01:30 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantEmployee Stock Option (right to buy) · Derivative | 217,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001193125-26-124724 · ownership.xml · derivative · entry 2 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,000 Underlying: Common Stock, $0.01 Par Value · 217,000 shares Expires 2036-03-23 F3 · derivative.exercise_date: 25% vesting on March 23, 2027 and thereafter 1/16th quarterly. Read SEC document |
| March 23, 2026 Filed Mar 26, 2026 01:30 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 221,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-124724 · ownership.xml · derivative · entry 1 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,000 Underlying: Common Stock, $0.01 Par Value · 221,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F2 · derivative.expiration_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| November 14, 2025 Filed Nov 15, 2025 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 18,777 | $5.03 | $94,448.31 |
DisclosureSEC source: 0001193125-25-283569 · ownership.xml · nonDerivative · entry 1 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,211 F1 · kind: Transaction occured pursuant to Rule 10B5-1 Plan established May 14, 2025. F2 · price: The weighted average sales price of the reported transaction was $5.03 based on a range of prices between $5.00 and $5.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 01:16 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 17,071 | $5.59 | $95,426.89 |
DisclosureSEC source: 0001193125-25-263121 · ownership.xml · nonDerivative · entry 1 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 473,988 F1 · kind: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2025 Filed Jul 18, 2025 00:48 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 15,450 | $3.85 | $59,482.50 |
DisclosureSEC source: 0000950170-25-096741 · ownership.xml · nonDerivative · entry 1 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 491,059 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 13, 2025 Filed May 16, 2025 00:37 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 145,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-073049 · ownership.xml · derivative · entry 2 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock, $0.01 Par Value · 145,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F4 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F4 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 13, 2025 Filed May 16, 2025 00:37 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 119,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-073049 · ownership.xml · nonDerivative · entry 1 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 506,509 F1 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on July 15, 2026 and each yearly anniversary thereof until fully vested. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · balance_after: Includes 2,093 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2024. Read SEC document |
| October 31, 2024 Filed Nov 5, 2024 02:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 17,071 | $7.07 | $120,691.97 |
DisclosureSEC source: 0000950170-24-121041 · ownership.xml · nonDerivative · entry 1 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 385,416 F1 · kind: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 23:50 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 5,372 | $5.83 | $31,318.76 |
DisclosureSEC source: 0000950170-24-084408 · ownership.xml · nonDerivative · entry 2 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 402,487 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| June 30, 2024 Filed Jul 17, 2024 23:50 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 3,362 | $3.09 | $10,388.58 |
DisclosureSEC source: 0000950170-24-084408 · ownership.xml · nonDerivative · entry 1 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 407,859 F1 · kind: Shares acquired through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 158,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062066 · ownership.xml · derivative · entry 2 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,000 Underlying: Common Stock, $.01 Par Value · 158,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $.01 Par Value | 129,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062066 · ownership.xml · nonDerivative · entry 1 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 404,497 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2025 and each yearly anniversary thereof until fully vested. Read SEC document |
| October 31, 2023 Filed Nov 3, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 17,071 | $4.29 | $73,234.59 |
DisclosureSEC source: 0001209191-23-054254 · doc4.xml · nonDerivative · entry 1 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,179 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032725 · doc4.xml · derivative · entry 2 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock, $.01 Par Value · 85,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.underlying_shares: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $.01 Par Value | 68,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032725 · doc4.xml · nonDerivative · entry 1 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,250 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2024 and each yearly anniversary thereof until fully vested. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit | 218,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-055685 · doc4.xml · nonDerivative · entry 1 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,500 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: 4-year vesting schedule with 1/4th of shares vesting on the first anniversary of the vesting determination date and on each anniversary thereafter until fully vested on the fourth anniversary of the vesting determination date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.